Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
G. N. Llewellyn, H.-Y. Chen, G. L. Rogers, X. Huang, P. Sell, J. E. Henley, P. M. Cannon
This study compares ACE2-derived and engineered Spike-binding peptide entry inhibitors against SARS-CoV-2 variants, finding that an optimized ACE2 derivative neutralizes all tested variants, while peptides show variable efficacy with resistance observed in Beta, Gamma, and Omicron variants.
bioRxiv · Jan 5, 2023 · PreprintMicrobiology